Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection

References

• Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016 Feb;3(1):15–21.
   PubMed Web of Science ®Google Scholar
• Arnold RS, Thom KA, Sharma S, et al. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 2011 Jan;104(1):40–45.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Deshpande LM, et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2008 Feb;52(2):570–573.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA approves new antibacterial drug. FDA News Release, [ updated August 2017 29; cited 2017 Oct 21]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm
   Google Scholar
• Vabomere [package insert]. Parsippany, NJ: The Medicines Company; 2017.
   Google Scholar
• Antibiotics currently in clinical development, May 2017. Pew Charitable Trusts. [cited 2017 Oct 9]. Available from: http://www.pewtrusts.org/~/media/assets/2017/05/antibiotics-currently-in-clinical-development-03-2017.pdf?la=en
   Google Scholar
• Fernandes P, Martens E. Antibiotics in late clinical development. Biochem Pharmacol. 2017 Jun;133:152–163.
   PubMed Web of Science ®Google Scholar
• Avycaz [package insert]. Irvine, CA: Allergan USA, Inc.; 2018.
   Google Scholar
• Zerbaxa [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2016.
   Google Scholar
• Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017 Jul 25;61(8):pii: e00883–17.
   Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016 Dec;63(12):1615–1618.
   PubMed Web of Science ®Google Scholar
• Krapp F, Grant JL, Sutton SH, et al. Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents. 2017 Jun;49(6):770–773.
   PubMed Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017 Feb;61(2):e01964–16.
   PubMed Web of Science ®Google Scholar
• King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017 Jun;61(7):pii: e00449–17.
   Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018 Jan;66(2):163–171.
   PubMed Web of Science ®Google Scholar
• Aitken SL, Kontoyiannis DP, DePombo AM, et al. Use of ceftolozane/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient. Pediatr Infect Dis. 2016 Sep;35(9):1040–1042.
   Google Scholar
• Hernandez-Tejedor A, Merino-Vega CD, Martin-Vivas A, et al. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam. Infection. 2017 Feb;45(1):115–117.
   PubMed Web of Science ®Google Scholar
• Caston JJ, De la Torre A, Ruiz-Camps I, et al. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2017 Feb;61(3):pii: e02136–16.
   Google Scholar
• Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010;65(suppl6):iii24–33.
   Google Scholar
• US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. [cited 2017 Feb 20]. Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
   Google Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007 May;67(7):1027–1052.
   PubMed Web of Science ®Google Scholar
• Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid b-lactamase inhibitor (RPX7009) with utility vs Class A serine carbapenemases. J Med Chem. 2015 May;58(9):3682–3692.
   PubMed Web of Science ®Google Scholar
• Codjoe FS, Donkor ES. Carbapenem Resistance: A Review. Med Sci (Basel). 2017 Dec 21;6(1):pii: E1.
   PubMedGoogle Scholar
• Papp-Wallace KM, Edimiani A, Taracila MA, et al. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011 Nov;55(11):4943–4960.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther. 2005 Feb;3(1):23–39.
   PubMedGoogle Scholar
• Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother. 2003 Sep;52(3):331–344.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three Decades of β-Lactamase Inhibitors. Clin Microbiol Rev. 2010 Jan;23(1):160–201.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Aug;61(9):pii: e00567–17.
   Web of Science ®Google Scholar
• Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2016 Aug;60(9):5454–5458.
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015 Aug;59(8):4856–4860.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Nov;61(11):e01443–17.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Lomovskaya O, Dudley MN, et al. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2018 Jan;62(1):e01907–17.
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Tsivkovski R. Vaborbactam (RPX7009) plus meropenem is active against the newly discovered BKC-1 and FRI-1 carbapenemases. Poster session presented at: 26th Annual European Congress of Clinical Microbiology and Infectious Diseases; 2016 Apr 9–12;Amsterdam, Netherlands.
   Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutant of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017 Dec;61(12):e01694–17.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother. 2015 Sep;59(9):5324–5330.
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017 Feb;61(3):e02097–16.
   PubMed Web of Science ®Google Scholar
• Munson E, Huband MD, Castanheira M, et al. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination. Diagn Microbiol Infect Dis. 2017 Dec;90(4):324–328.
   PubMed Web of Science ®Google Scholar
• Rubio-Aparicio D, Loutit J, Dudley M, et al. Potency of meropenem-vaborbactam in lung surfactant. Antimicrob Agents Chemother. 2017 Dec;62(1):e01702–17.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005 Jun;191(12):2149–2152.
   PubMed Web of Science ®Google Scholar
• Griffith D, Loutit J, Morgan E, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor RPX7009 in healthy adult subjects. Antimicrob Agents Chemother. 2016 Oct;60(10):6326–6332.
   PubMed Web of Science ®Google Scholar
• Wenzler E, Gotfried MH, Loutit JS, et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015 Dec;59(12):7232–7239.
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Loutit JS, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects. Antimicrob Agents Chemother. 2018 Feb;62(4):e02228–17.
   Web of Science ®Google Scholar
• Zhanel GG, Simor AE, Vercaigne L, et al. Imipenem and meropenem comparison of in vitro activity, pharmacokinetics, clinical trials, and adverse effects. Can J Infect Dis. 1998 Aug/Jul;9(4):215–228.
   PubMedGoogle Scholar
• Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother. 1995 Jul;36(Suppl):A:43–56.
   Google Scholar
• Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008 Sep;47(Suppl 1):S32–40.
   PubMed Web of Science ®Google Scholar
• Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989 Sep;24(Suppl):A:311–320.
   PubMedGoogle Scholar
• Frippiat F, Musuamba FT, Seidel L, et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2015 Jan;70(1):207–216.
   PubMed Web of Science ®Google Scholar
• Griffith D, Rubino C, Loutit J, et al. A phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor RPX7009 alone, meropenem alone, and both in combination (Carbavance) TID for 7 days in healthy adult subjects. Open Forum Infect Dis. 2014;1(S1:S154–155.
   Google Scholar
• The Medicines Company. A Phase IIIb, multicenter, double-blind, randomized, comparative study to evaluate the efficacy, safety, and tolerability of meropenem-vaborbactam versus piperacillin/Tazobactam in the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in hospitalized adults (TANGO III). NLM identifier: NCT03006679 [cited Dec 19, 2017]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03006679?term=vaborbactam&rank=1
   Google Scholar
• Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, et al. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005 Mar;39(3):533–537.
   PubMed Web of Science ®Google Scholar
• De Turck BJG, Diltoer MW, Cornelis PJWW, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother. 1998 Oct;42(4):563–564.
   PubMed Web of Science ®Google Scholar
• Haroutiunian S, Ratz Y, Rabinovich B, et al. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study. J Clin Pharmacol. 2009 Nov;49(11):1363–1369.
   PubMed Web of Science ®Google Scholar
• Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004 Sep;31(3):232–234.
   PubMed Web of Science ®Google Scholar
• Spriet I, Goyens J, Meersseman W, et al. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007 Jul;41(7):1130–1136.
   PubMed Web of Science ®Google Scholar
• FDA medical review: Vabomere (meropenem and vaborbactam), 2017. [accessed 2017 Oct 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209776Orig1s000MedR.pdf
   Google Scholar
• Rempex Pharmaceuticals. Dose-finding, pharmacokinetics, safety, and tolerability of meropenem-vaborbactam in pediatric subjects with serious bacterial infections. NLM identifier: NTC02687906 [cited Oct 10, 2017]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02687906?term=vaborbactam&rank=1
   Google Scholar
• Rubino CM, Bhavnani SM, Loutit JS, et al. Meropenem-vaborbactam: single-dose pharmacokinetics and safety in subjects with chronic renal impairment. Antimicrob Agents Chemother. 2018 Jan;62(3):e02103–17.
   Web of Science ®Google Scholar
• Bhave P, Tregaskis P, Walker R, et al. Intraperitoneal meropenem for peritoneal dialysis peritonitis with Serratia marcescens immediately on commencing dialysis. New Microbes New Infect. 2016 Jan;10:84–86.
   PubMedGoogle Scholar
• de Fijter CW, Jakulj L, Amiri F, et al. Intraperitoneal meropenem for polymicrobial peritoneal dialysis-related peritonitis. Perit Dial Int. 2016. 9–10. 36(5):572–573.
   PubMed Web of Science ®Google Scholar
• Wiesholzer M, Pichler P, Reznicek G, et al. Pharmacokinetic profile of meropenem after intraperitoneal and intravenous administration in patients receiving automated peritoneal dialysis (APD): an open, randomized, single center cross over descriptive pharmacokinetic study. Antimicrob Agents Chemother. 2016 Apr;60(5):2790–2797.
   PubMed Web of Science ®Google Scholar
• Van Ende C, Tintillier M, Cuvelier C, et al. Intraperitoneal meropenem administration: a possible alternative to the intravenous route. Perit Dial Int. 2010 Mar-Apr;30(2):250–251.
   PubMed Web of Science ®Google Scholar
• Vlaar PJ, van Hulst M, Benne CA, et al. Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis. Perit Dial Int. 2013 Nov-Dec;33(6):708–709.
   PubMed Web of Science ®Google Scholar
• Giles LJ, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care units receiving continuous veno-venous hemofiltration or hemidialfiltration. Crit Care Med. 2000;28:632–637.
   PubMed Web of Science ®Google Scholar
• Jamal JA, Mat-Nor MB, Mohamad-Nor FS, et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomized controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2015 Jan;45(1):41–45.
   PubMed Web of Science ®Google Scholar
• Nehus EJ, Mouksassi S, Vinks AA, et al. Meropenem in children receiving continuous renal replacement therapy: clinical trial simulations using realistic covariates. J Clin Pharmacol. 2014 Dec;54(12):1421–1428.
   PubMed Web of Science ®Google Scholar
• Ververs T, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med. 2000;28:3412–3416.
   PubMed Web of Science ®Google Scholar
• Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005 Oct;41(8):1159–1166.
   PubMed Web of Science ®Google Scholar
• Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. Clin Pharmacokinet. 2015 Sep;54(9):933–941.
   PubMed Web of Science ®Google Scholar
• Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol. 2014 Mar;54(3):324–330.
   PubMed Web of Science ®Google Scholar
• Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013 Feb;57(2):708–715.
   PubMed Web of Science ®Google Scholar
• Binder L, Schworer H, Hoppe S, et al. Pharmacokinetics of meropenem in critically ill patients with severe infections. The Drug Monit. 2013 Feb;35(1):63–70.
   PubMed Web of Science ®Google Scholar
• Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label trial. Crit Care. 2012 Jun;16(3):R113.
   PubMed Web of Science ®Google Scholar
• Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet. 2005;44:539–549.
   PubMed Web of Science ®Google Scholar
• Dagan R, Velghe L, Rodda JL, et al. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother. 1994 Jul;34(1):175–179.
   PubMed Web of Science ®Google Scholar
• Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem meningitis study group. J Antimicrob Chemother. 1995 Jul;36(Suppl):A:85–97.
   PubMedGoogle Scholar
• Blassmann U, Roehr AC, Frey OR, et al. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Crit Care. 2016 Oct;20(1):343.
   PubMedGoogle Scholar
• Craig WA, Ebert S, Watanabe Y Differences in time above MIC (T > MIC) required for efficacy of β-lactams in animal infection T 1 MIC models [abstract 86]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993.
   Google Scholar
• Ong CR, Tessier PR, Li C, et al. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis. 2007 Feb;57(2):153–161.
   PubMed Web of Science ®Google Scholar
• Mattoes HM, Kuti JL, Drusano GL, et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004 Aug;26(8):1187–1198.
   PubMed Web of Science ®Google Scholar
• Maglio D, Banevicius MA, Sutherland C, et al. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother. 2005 Jan;49(1):276–280.
   PubMed Web of Science ®Google Scholar
• Griffith D, Sabet M, Tarazi Z, et al. Pharmacodynamics of vaborbactam when administered in combination with meropenem. Poster presentation at the 2nd ASM Microbe Conference; 2017 Jun 1–5; New Orleans, LA.
   Google Scholar
• Sabet M, Tarazi Z, Nolan T, et al. Activity of meropenem-vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Dec;62(1):pii: e01446–17.
   Web of Science ®Google Scholar
• Sabet M, Tarazi Z, Rubio-Aparicio D, et al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob Agents Chemother. 2018 Jan;62(2):pii: e01969–17.
   Web of Science ®Google Scholar
• Bhavnani SM, Trang M, Griffith DC, et al. Meropenem-vaborbactam pharmacokinetic-pharmacodynamic target attainment analyses as support for dose selection in patients with normal renal function and varying degrees of renal impairment. Poster session presented at: 6th Annual ID Week; 2017 Oct 4–8; San Diego, CA.
   Google Scholar
• Weiss WJ, Pulse ME, Nguyen P, et al. Activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae in a murine model of pyelonephritis. Antimicrob Agents Chemother. 2018 Jan;62(1):e01439–17.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Bhowmick T, Metallidis S. Effect of meropenen-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018 Feb;319(8):788–799.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Bhowmick T, Darouiche RO, et al. Per pathogen outcomes of meropenem-vaborbactam (M-V) versus piperacillin-tazobactam (P-T) in the treatment of adults with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), in TANGO 1, a phase 3 randomized, double-blind, double-dummy trial. Poster presentation at the 27th European Congress of Clinical Microbiology and Infectious Diseases Conference, Vienna, Austria.
   Google Scholar
• Kaye KS, Vazquez J, Mathers A, et al. Meropenem-vaborbactam (Vabomere) vs. best available therapy for CRE infections: TANGO II randomized, controlled phase 3 study results. Poster session presented at: 6th Annual ID Week; 2017 Oct 4–8; San Diego, CA.
   Google Scholar
• The Medicines Company announces TANGO-II trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE [news release]. Parsippany, NJ: The Medicines Company. [ updated 2017 July 25; cited 2017 Oct 10]. Available from: http://www.themedicinescompany.com/investors/news/medicines-company-announces-TANGO-II-trial-meropenem-vaborbactam-formerly-carbavance
   Google Scholar
• Wunderink R, Giamarellos-Bourboulis EJ, Rahav G, et al. Meropenem-vaborbactam (VABOMERE) vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection. Poster session presented at: 6th Annual ID Week; 2017 Oct 4–8; San Diego, CA.
   Google Scholar
• Paterson D, Kwak EJ, Bhowmick T, et al. Meropenem-vaborbactam (VABOMERE) vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO-II: outcomes in immunocompromised patients. Poster session presented at: 6th Annual ID Week; 2017 Oct 4–8; San Diego, CA.
   Google Scholar
• Mathers A, Hope W, Kaye KS, et al. Meropenem-vaborbactam (VABOMERE): outcomes in subjects with renal impairment in phase 3 studies TANGO I and II. Poster session presented at: 6th Annual ID Week; 2017 Oct 4–8; San Diego, CA.
   Google Scholar
• Lomovskaya O, Castanheira M, Vazquez J, et al. Assessment of MIC increases with meropenem-vaborbactam (VABOMERE) and ceftazidime-avibactam in TANGO II (a phase 3 study of the treatment of CRE infections). Poster session presented at: 6th Annual ID Week; 2017 Oct 4–8; San Diego, CA.
   Google Scholar
• Meropenem [package insert]. Lake Forest, IL: Hospira, Inc.; 2017.
   Google Scholar
• Unasyn [package insert]. New York, NY: Pfizer, Inc.; 2017.
   Google Scholar
• Zosyn [package insert]. Philadelphia, PA: Pfizer, Inc.; 2012.
   Google Scholar
• Timentin [package insert]. Research Triangle Park, NC: GlaxoSmithKline PLC; 2014.
   Google Scholar
• Kidd JM, Avery LM, Asempa TE, et al. Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated Y-site administration. Clin Ther. 2018Feb;40(2):261–269.
   PubMed Web of Science ®Google Scholar
• The Medicines Company announces closing of divestiture of infectious disease business unit to Melinta Therapeutics [news release]. Parsippany, NJ: The Medicines Company. [ updated 2018 January 8; cited 2018 Feb 21]. Available from: http://www.themedicinescompany.com/investors/news/medicines-company-announces-closing-divestiture-infectious-disease-business-unit
   Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 2018 Jan;78(1):65–98.
   Google Scholar